Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

~ ACHIEVED SECOND QUARTER 2025 TOTAL NET REVENUESOF $9.7 MILLION ~ ~ DOUBLE DIGIT NEW ACCOUNTS IN THE SECOND QUARTER OF 2025, INCLUDING NOTABLE QUARTER-OVER-QUARTER GROWTH IN BOTH LARGE COMMUNITY PRACTICES AND ACADEMIC CENTERS, SUPPORTED BY TARGETED SALES STRATEGY AND ENHANCED PATIENT SUPPORT SERVICES FOR PEDMARK  ~ ~ SUCCESSFUL INITIAL UPTAKE OF PEDMARQSI IN THE UNITED KINGDOM AND GERMANY WITH ADDITIONAL EU LAUNCHES PLANNED ~ ~ JAPAN CLINICAL TRIAL (STS-J01) RESULTS EXPECTED IN THE SECOND HALF OF 2025 WITH EVALUATION OF BOTH REGISTRATION AND PARTNERING OR LICENSING EXPECTED THEREAFTER ~ ~ MANAGEMENT TO HOST CONFERENCE CALL TODAY AT8:30 A.M. ET~ RESEARCH TRIANGLE PARK, N.C.

FENNEC PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

RESEARCH TRIANGLE PARK, N.C., AUG. 11, 2025 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (NASDAQ: FENC; TSX: FRX), A COMMERCIAL STAGE SPECIALTY PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE ITS SECOND QUARTER 2025 FINANCIAL RESULTS BEFORE THE OPENING OF THE U.S. FINANCIAL MARKETS ON THURSDAY, AUGUST 14, 2025. MANAGEMENT WILL HOST A CONFERENCE CALL AND WEBCAST THAT DAY TO DISCUSS THE COMPANY'S FINANCIAL AND BUSINESS RESULTS.

FENNEC PHARMACEUTICALS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 14, 2025

RESEARCH TRIANGLE PARK, N.C., JUNE 03, 2025 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (THE COMPANY) (NASDAQ:FENC) (TSX:FRX) TODAY ANNOUNCED THAT THE NOMINEES LISTED IN THE MANAGEMENT PROXY CIRCULAR DATED APRIL 25, 2025 WERE ELECTED AS DIRECTORS OF THE COMPANY AT THE ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS HELD IN NEW YORK, NEW YORK ON JUNE 3, 2025.

FENNEC ANNOUNCES RESULTS OF ANNUAL MEETING

RESEARCH TRIANGLE PARK, N.C., MAY 08, 2025 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (NASDAQ: FENC; TSX: FRX), A COMMERCIAL STAGE SPECIALTY PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE ITS FIRST QUARTER 2025 FINANCIAL RESULTS BEFORE THE OPENING OF THE U.S. FINANCIAL MARKETS ON TUESDAY, MAY 13, 2025. MANAGEMENT WILL HOST A CONFERENCE CALL AND WEBCAST THAT DAY TO DISCUSS THE COMPANY'S FINANCIAL AND BUSINESS RESULTS.

FENNEC PHARMACEUTICALS TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS ONMAY 13, 2025

~ ACHIEVED FULL-YEAR PEDMARK  NET PRODUCT SALES OF $29.6 MILLION, UP 40% YEAR-OVER-YEAR, AND GENERATED PEDMARK  Q4 2024 NET PRODUCT SALES OF $7.9 MILLION ~

FENNEC PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

RESEARCH TRIANGLE PARK, N.C., MARCH 06, 2025 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (NASDAQ: FENC; TSX: FRX), A COMMERCIAL STAGE SPECIALTY PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT THE COMPANY WILL RELEASE ITS FULL YEAR AND FOURTH QUARTER 2024 FINANCIAL RESULTS BEFORE THE OPENING OF THE U.S. FINANCIAL MARKETS ON MONDAY, MARCH 10, 2025. MANAGEMENT WILL HOST A CONFERENCE CALL AND WEBCAST THAT DAY TO DISCUSS THE COMPANY'S FINANCIAL AND BUSINESS RESULTS.

FENNEC PHARMACEUTICALS TO REPORT FULL YEAR AND FOURTH QUARTER 2024 FINANCIAL RESULTS ON MARCH 10, 2025

~ PEDMARQSIIS THE FIRST AND ONLY APPROVED THERAPY IN THE EU ANDU.K.FOR THE PREVENTION OF OTOTOXICITY, OR HEARING LOSS, INDUCED BY CISPLATIN CHEMOTHERAPY IN PATIENTS 1 MONTH TO

FENNEC PHARMACEUTICALS ANNOUNCES COMMERCIAL LAUNCH OF PEDMARQSI IN GERMANY

~ PEDMARQSI (ANHYDROUS SODIUM THIOSULFATE) IS THE FIRST AND ONLY TREATMENT AVAILABLE WITHIN NHS ENGLAND AND WALES FOR THE PREVENTION OF CISPLATIN-INDUCED OTOTOXICITY (HEARING LOSS) IN CHILDREN AND YOUNG PEOPLE (1 MONTH-17 YEARS OF AGE) ~

FENNEC PHARMACEUTICALS ANNOUNCES PEDMARQSI POSITIVE RECOMMENDATION BY NICE FOR THE PREVENTION OF CISPLATIN-INDUCED HEARING LOSS IN ENGLAND AND WALES

~ $13 MILLION CONVERTIBLE DEBT REPAYMENT FROM AVAILABLE CASH ~ ~ ELIMINATION OF APPROXIMATELY $1.5 MILLION IN ANNUAL INTEREST EXPENSE AND POTENTIAL EQUITY OVERHANG OF APPROXIMATELY 1.6 MILLION SHARES ~ RESEARCH TRIANGLE PARK, N.C., DEC. 19, 2024 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (NASDAQ:FENC; TSX: FRX), A SPECIALTY PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THE EARLY REPAYMENT OF $13 MILLION OF THE COMPANY'S APPROXIMATELY $32 MILLION OUTSTANDING CONVERTIBLE DEBT FACILITY WITH PETRICHOR HEALTHCARE CAPITAL MANAGEMENT (PETRICHOR).

FENNEC PHARMACEUTICALS ANNOUNCES EARLY PARTIAL REPAYMENT OF ITS OUTSTANDING CONVERTIBLE DEBT FACILITY WITH PETRICHOR HEALTHCARE CAPITAL MANAGEMENT

RESEARCH TRIANGLE PARK, N.C., DEC. 12, 2024 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (NASDAQ:FENC; TSX: FRX), A COMMERCIAL STAGE SPECIALTY PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT THE COMPANY WILL BE PARTICIPATING IN THE VIRTUAL H.C. WAINWRIGHT @ HOME FIRESIDE CHAT SERIES TAKING PLACE ON MONDAY, DECEMBER 16, 2024 AT 11:00 A.M. ET.

FENNEC PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCE

RESEARCH TRIANGLE PARK, N.C., NOV. 13, 2024 (GLOBE NEWSWIRE) -- FENNEC PHARMACEUTICALS INC. (NASDAQ:FENC; TSX: FRX), A COMMERCIAL STAGE SPECIALTY PHARMACEUTICAL COMPANY, TODAY ANNOUNCED THAT THE COMPANY WILL BE PARTICIPATING IN THE 15TH ANNUAL CRAIG-HALLUM ALPHA SELECT CONFERENCE. THE COMPANY'S MANAGEMENT WILL BE AVAILABLE FOR ONE-ON-ONE MEETINGS THROUGHOUT THE EVENT.

~ ACHIEVED THIRD QUARTER 2024 NET PRODUCT SALES OF $7.0 MILLION ~ ~ INCREASING MOMENTUM AND SUCCESSFUL REIMBURSEMENT IN THE ADOLESCENT AND YOUNG ADULT (AYA) SEGMENT FOLLOWING STRATEGIC INVESTMENTS TO DRIVE AWARENESS OF OTOTOXICITY & ADOPTION OF PEDMARK ~ ~ STRENGTHENED EXECUTIVE LEADERSHIP TEAM WITH CHIEF MEDICAL OFFICER, CHIEF COMMERCIAL OFFICER & CHIEF STRATEGY OFFICER APPOINTMENTS ~ ~ COMPANY HAS APPROXIMATELY $40 MILLION IN CASH, CASH EQUIVALENTS, AND INVESTMENT SECURITIES EXPECTED TO FUND OPERATIONS INTO AT LEAST 2026 ~ ~ MANAGEMENT TO HOST CONFERENCE CALL TODAY AT8:30 A.M. ET~ RESEARCH TRIANGLE PARK, N.C.

Fennec Pharmaceuticals Inc.

FENC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Fennec Pharmaceuticals Inc.

FENC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

FENC